(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

ACELLYTRON THERAPEUTICS

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: CombinedOffice: United States

Quick snapshot

ACELLYTRON THERAPEUTICS

ST13

US500000079406657

Class

5, 35, 42, 44

Filing

79406657

Registration

7797742

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

25

Latest update

04/03/2026

Trademark type

Combined

Nice classes

5, 35, 42, 44

Filing date

03/08/2024

Registration date

05/20/2025

Expiration date

-

Complete case details

Structured fields from the responsible authority and the official record.

Status date

05/20/2025

Last transaction

04/03/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

3

Owner type

03

Owner location

CN

Examiner

JACKSON, STEVEN W

Law office

L70

Current location

FILE REPOSITORY (FRANCONIA)

Mark description

The mark consists of the stylized wording "ACELLYTRON THERAPEUTICS" with a double strand DNA inside the stylized letter "O".

Holders and representatives

Holders

Wuxi Biologics (Shanghai) Co., Ltd.

Representatives

Michael T. Smith Birch Stewart Kolasch & Birch LLP

Technical classification

Nice Classes

Class 5Class 35Class 42Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Chemical-pharmaceutical preparations for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; biochemical medicines for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; vaccine preparations; influenza vaccine; chemotherapeutics; stem cells for medical purposes; medicines for human purposes for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; drugs for medical purposesmedicines for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; pharmaceutical preparations for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer; drugs for treatment of cancer; medical preparation for treating diseases and disorders related to the immune system; biological agentbiological preparations for treating cancer; pharmaceutical preparations for the prevention and treatment of cancer; living cells for medical use; medical cell inhibitor for inhibiting the growth of cancer cells; reagents for medical purposes; anticancer agent; diagnostic reagents for medical purposes; pharmaceutical preparationstumor suppressor; cells for medical use; dietetic infusionssugarfoodsbeverages substances adapted for medical use; biological preparations for veterinary purposes for the treatment of autoimmuneneurodegenerativemetabolicviral and infectious diseasesfor the treatment of cancer

Class 35

Online advertising on a computer network; advertising services; publicity agents; dissemination of advertising and advertising matter in the nature of flyersprospectusesbrochuresleaflets and samples; providing commercial information and advice for consumers in the choice of products and services; organization of exhibitions and trade fairs for commercial or advertising purposes; import-export agency services; marketing; sponsorship search; retail store services for pharmaceuticalveterinary and sanitary preparations and medical supplies; wholesale store services for pharmaceuticalveterinary and sanitary preparations and medical supplies

Class 42

Research and development of new products for others; technological research in the field of chemical and biological medicaments; chemical analysis; biochemical research and analysis; research and development in the field of pharmaceutical preparations; medical research service; research and development of services in the field of antibodies; stem cell research services; medical research; medical and scientific researchconducting clinical trials for others; biological research; computer programming in the field of medical aspects

Class 44

Preparation of prescriptions by pharmacists; stem cell therapy services; medical clinic services; providing medical information; DNA screening for medical purposes; medical analysis services for the diagnosis of cancer; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical screening; health care; medical assistance

Publications

History of USPTO decisions and trademark events.

25 publications found

OPNX

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB

03/26/2026

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

03/09/2026

OPNR

NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB

03/09/2026

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

01/08/2026

FICS

FINAL DISPOSITION NOTICE SENT TO IB

12/19/2025

FIMP

FINAL DISPOSITION PROCESSED

12/19/2025

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

08/21/2025

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

05/20/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

05/20/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/01/2025

PUBO

PUBLISHED FOR OPPOSITION

04/01/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

03/26/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/06/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

03/04/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

03/04/2025

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

03/04/2025

RFNT

REFUSAL PROCESSED BY IB

11/17/2024

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

10/30/2024

RFRR

REFUSAL PROCESSED BY MPU

10/30/2024

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

10/25/2024

CNRT

NON-FINAL ACTION WRITTEN

10/24/2024

DOCK

ASSIGNED TO EXAMINER

10/17/2024

MAFR

APPLICATION FILING RECEIPT MAILED

10/16/2024

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

10/16/2024

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

10/10/2024

Continuous trademark protection

Get notified about every new filing that threatens ACELLYTRON THERAPEUTICS or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.